DiaMedica Therapeutics Inc. (DMAC)
NasdaqCM
Price as at 13 Aug 2026, 16:06 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
DiaMedica Therapeutics Inc. trades at USD6.83. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
4 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Leon Cooperman, COOPERMAN LEON G$24.29M · 0.7% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$5.95M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$1.03M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$78.3K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own DMAC?
4 of the institutions we track reported a position in DMAC in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its DMAC data?
Fundamentals for DMAC come from company filings and exchange data, as listed on NasdaqCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 13 Aug 2026, 16:06 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for DMAC, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.